PECS II Block and Single Port Robot-assisted Transaxillary Thyroidectomy
Study on the PECS II Block With Postoperative Pain in Patients Undergoing Single Port Robot-assisted Transaxillary Thyroidectomy: Double-blinded Randomized Controlled Trial
1 other identifier
interventional
76
0 countries
N/A
Brief Summary
The da Vinci robotic system was developed to improve both operative maneuverability (through multi-articulated instruments) and the surgical view (via a three-dimensional camera). Although the system has many advantages, skin incision, wide flap dissection, and pneumatic/mechanical retraction remain essential, but cause postoperative pain and slower recovery. Previous studies found that pectoralis fascial blocks were easy to establish; local anesthetics are injected between two adjacent myofascial layers under ultrasound guidance, providing the surgeon with a clear image. Analgesic efficacy has been validated during robotic thyroidectomy in our institution. The pain outcomes were comparable between the groups, but there were fewer complications in the PECS II group. The investigators investigated whether this block can reduce postoperative pain during wide flap dissection for single-port robot-assisted transaxillary thyroidectomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2024
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 19, 2023
CompletedFirst Posted
Study publicly available on registry
October 25, 2023
CompletedStudy Start
First participant enrolled
January 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2024
CompletedJanuary 5, 2024
January 1, 2024
9 months
October 19, 2023
January 3, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Analgesic efficacy
Visual analog scale from 0 (minimum) to 10 (maximum)
the day after surgery
Secondary Outcomes (1)
Quality of postoperative surgery course
the day after surgery
Study Arms (2)
PECS II block group
EXPERIMENTALNo PECS II block group
NO INTERVENTIONInterventions
An ultrasound probe was placed obliquely over the second and third ribs below the lateral one-third of the clavicle. After identification of the anatomical structures, the needle was advanced along a superior-medial-to-inferior-lateral passage to the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL ropivacaine (0.375% w/v) was injected at the level of the third rib. The anesthetic spread around the axilla, and the needle was withdrawn to the point in the plane between the pectoralis major and minor muscles. A second injection of 20 mL ropivacaine (0.375% w/v) was then delivered (PECS II).
Eligibility Criteria
You may qualify if:
- Patients aged 19 to 60 years who are scheduled to undergo single-port robot thyroidectomy (lobectomy or total thyroidectomy)
- Patients with cancer stages T1 or T2 (less than 4 cm without invasion of surrounding tissue) when thyroid cancer is suspected in the preoperative examination
- Patients with nodules with a maximum length of less than 4 cm based on ultrasonography if thyroid cancer is not suspected in the preoperative examination
- Patients with a BMI greater than or equal to 18.5 and less than 30.0.
You may not qualify if:
- Patients requiring lateral cervical lymph node dissection
- pregnant women
- Uncontrolled diabetes
- Chronic kidney failure
- Patients with previous neck surgery
- Patients with Graves' disease
- People with chronic alcoholism
- Patients with vocal cord paralysis before surgery
- Severe obese patients with a body mass index \>35 kg/m2
- Patients participating in another clinical trial within 30 days
- Patients who expect that it will be difficult for medical staff to fill out the questionnaire on their own
- Patients whose medical staff determines that participation in the study is difficult due to other underlying diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Min Suk Chaelead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
October 19, 2023
First Posted
October 25, 2023
Study Start
January 4, 2024
Primary Completion
September 28, 2024
Study Completion
September 30, 2024
Last Updated
January 5, 2024
Record last verified: 2024-01